NASDAQ:CDT Conduit Pharmaceuticals (CDT) Stock Price, News & Analysis $0.62 +0.03 (+5.08%) Closing price 04/9/2025 04:00 PM EasternExtended Trading$0.60 -0.02 (-3.39%) As of 04/9/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Conduit Pharmaceuticals Stock (NASDAQ:CDT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CDT alerts:Sign Up Key Stats Today's Range$0.51▼$0.6350-Day Range$0.59▼$2.8552-Week Range$0.51▼$350.00Volume388,701 shsAverage Volume1.07 million shsMarket Capitalization$4.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewConduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Read More… Remove Ads Conduit Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreCDT MarketRank™: Conduit Pharmaceuticals scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Conduit Pharmaceuticals.Read more about Conduit Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Conduit Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Conduit Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Conduit Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted105.83% of the float of Conduit Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverConduit Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Conduit Pharmaceuticals has recently increased by 66.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldConduit Pharmaceuticals does not currently pay a dividend.Dividend GrowthConduit Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted105.83% of the float of Conduit Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverConduit Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Conduit Pharmaceuticals has recently increased by 66.57%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.23 News SentimentConduit Pharmaceuticals has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Conduit Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for CDT on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows4 people have added Conduit Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Conduit Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders30.93% of the stock of Conduit Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.29% of the stock of Conduit Pharmaceuticals is held by institutions.Read more about Conduit Pharmaceuticals' insider trading history. Receive CDT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CDT Stock News HeadlinesConduit expands parntership with SarborgApril 8 at 10:57 AM | markets.businessinsider.comConduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline OptimizationApril 7 at 11:26 AM | markets.businessinsider.comFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money isn't legally yours. Now, think your savings are safe? Think again.April 10, 2025 | Priority Gold (Ad)Analyzing Conduit Pharmaceuticals (CDT) and Its PeersApril 6, 2025 | americanbankingnews.comConduit Pharmaceuticals receives U.S. patent approval for AZD1656April 2, 2025 | markets.businessinsider.comConduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune DiseasesMarch 31, 2025 | globenewswire.comConduit Pharmaceuticals Reports Significant R&D Advancements in Lupus Studies and Pipeline DevelopmentMarch 21, 2025 | nasdaq.comConduit Pharma Highlights Progress In Lupus Studies, Phase II Trial For AZD1656March 21, 2025 | nasdaq.comSee More Headlines CDT Stock Analysis - Frequently Asked Questions How have CDT shares performed this year? Conduit Pharmaceuticals' stock was trading at $6.86 on January 1st, 2025. Since then, CDT stock has decreased by 91.0% and is now trading at $0.62. View the best growth stocks for 2025 here. How were Conduit Pharmaceuticals' earnings last quarter? Conduit Pharmaceuticals Inc. (NASDAQ:CDT) announced its quarterly earnings data on Friday, March, 28th. The company reported ($20.33) EPS for the quarter. When did Conduit Pharmaceuticals' stock split? Conduit Pharmaceuticals shares reverse split before market open on Monday, January 27th 2025. The 1-100 reverse split was announced on Thursday, January 23rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Conduit Pharmaceuticals? Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Conduit Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Conduit Pharmaceuticals investors own include BIOLASE (BIOL), Daré Bioscience (DARE), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Cara Therapeutics (CARA), Canoo (GOEV) and Jiuzi (JZXN). Company Calendar Last Earnings3/28/2025Today4/10/2025Next Earnings (Estimated)4/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDT Previous SymbolNASDAQ:CDT CIK1896212 Webwww.conduitpharma.com Phone760-471-8536FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($39.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-540,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-328.67% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.62) per share Price / Book-1.00Miscellaneous Outstanding Shares6,663,000Free Float710,000Market Cap$4.13 million OptionableNot Optionable Beta2.37 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CDT) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersThe Most Bullish Metric For Stocks (NOT Volume…)Before placing a single trade, Tim Sykes always checks one key bullish metric. It’s the same signal that has s...MillPub | SponsoredTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredBITCOINYou're not going to believe this. There's a bizarre new way to make money from crypto... ...and it's not...Awesomely, LLC | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.